Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

X-linked creatine transporter deficiency results in prolonged QTc and increased sudden death risk in humans and disease model

Abstract

Purpose

Creatine transporter deficiency (CTD) is a rare X-linked disorder of creatine transport caused by pathogenic variants in SLC6A8 (Xq28). CTD features include developmental delay, seizures, and autism spectrum disorder. This study was designed to investigate CTD cardiac phenotype and sudden death risk.

Methods

We performed a cross-sectional analysis of CTD males between 2017 and 2020. Subjects underwent evaluation with electrocardiogram (ECG), echocardiography, and ambulatory ECG with comparable analysis in creatine transporter deficient mice (Slc6a8−/y) using ECG, echocardiography, exercise testing, and indirect calorimetry.

Results

Eighteen subjects with CTD (18 males, age 7.4 [3.8] years) were evaluated: seven subjects (39%) had QTc ≥ 470 milliseconds: 510.3 ± 29.0 vs. 448.3 ± 15.9, P < 0.0001. The QTc ≥ 470 milliseconds cohort had increased left ventricular internal dimension (diastole) ([LVIDd] Z-score: 0.22 ± 0.74, n = 7 vs. −0.93 ± 1.0, n = 11, P = 0.0059), and diminished left ventricular posterior wall dimension (diastole) ([LVPWDd, in mm]: 5.0 ± 0.6, n = 7 vs. 5.7 ± 0.8, n = 11, P = 0.0183), when compared to subjects with normal or borderline QTc prolongation. Similar ECG and echocardiographic abnormalities were seen in Slc6a8−/y mice. Additionally, Slc6a8−/y mice had diminished survival (65%).

Conclusion

Prolonged QTc and abnormal echocardiographic parameters consistent with developing cardiomyopathy are seen in some male subjects with CTD. Slc6a8−/y mice recapitulated these cardiac abnormalities. Male CTD subjects may be at increased risk for cardiac dysfunction and sudden death.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Human and mouse electrocardiogram (ECGs) demonstrate prolonged QTc and echocardiographic data consistent with cardiomyopathy.
Fig. 2: Slc68a−/y mouse model echocardiographic data 3 and 9 months demonstrates preserved systolic function, LV chamber dilation, and increased LV was thickness.
Fig. 3: Three-month Slc6a8−/y mice show increased VO2, diminished exercise capacity, and shorter time to exhaustion.
Fig. 4: Slc6a8−/y mice show significantly diminished survival probability and increased unexpected death incidence when compared to controls.

Data availability

Data will be made available upon request to first, corresponding, or senior authors. Genomic data will be made available provided related NIH and NICHD privacy guidelines can be fully met. De-identified genomic data will be provided upon request.

References

  1. 1.

    Rosenberg, E. H. et al. Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application. Hum. Mutat. 28, 890–896 (2007).

    CAS  Article  Google Scholar 

  2. 2.

    Mercimek-Mahmutoglu, S. & Salomons, G. S. in GeneReviews (eds Adam, M. P. et al.) Creatine deficiency syndromes (University of Washington, Seattle, 1993).

  3. 3.

    Rosenberg, E. H. et al. High prevalence of SLC6A8 deficiency in x-linked mental retardation. Am. J. Hum. Genet. 75, 97–105 (2004).

    CAS  Article  Google Scholar 

  4. 4.

    Newmeyer, A., Cecil, K. M., Schapiro, M., Clark, J. F. & Degrauw, T. J. Incidence of brain creatine transporter deficiency in males with developmental delay referred for brain magnetic resonance imaging. J. Dev. Behav. Pediatr. 26, 276–282 (2005).

    Article  Google Scholar 

  5. 5.

    Stromberger, C., Bodamer, O. A. & Stöckler-Ipsiroglu, S. Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J. Inherit. Metab. Dis. 26, 299–308 (2003).

    CAS  Article  Google Scholar 

  6. 6.

    Neubauer, S. et al. Downregulation of the Na+-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation. 100, 1847–1850 (1999).

    CAS  Article  Google Scholar 

  7. 7.

    Guimbal, C. & Kilimann, M. W. A Na+-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. J. Biol. Chem. 268, 8418–8421 (1993).

    CAS  Article  Google Scholar 

  8. 8.

    Salomons, G. S. et al. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am. J. Hum. Genet. 68, 1497–1500 (2001).

    CAS  Article  Google Scholar 

  9. 9.

    van de Kamp, J. M. et al. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. J. Med. Genet. 50, 463 (2013).

    Article  Google Scholar 

  10. 10.

    Anselm, I. A., Coulter, D. L. & Darras, B. T. Cardiac manifestations in a child with a novel mutation in creatine transporter gene SLC6A8. Neurology. 70, 1642–1644 (2008).

    Article  Google Scholar 

  11. 11.

    Nozaki, F., Kumada, T., Shibata, M., Fujii, T., Wada, T. & Osaka, H. A family with creatine transporter deficiency diagnosed with urinary creatine/creatinine ratio and the family history: the third Japanese familial case. Hattatsu Brain Dev. 47, 49–52 (2015).

    Google Scholar 

  12. 12.

    Priori, S. G. et al. Risk stratification in the long-QT syndrome. N. Engl. J. Med. 348, 1866–1874 (2003).

    Article  Google Scholar 

  13. 13.

    Baroncelli, L. et al. A novel mouse model of creatine transporter deficiency. F1000research. 3, 228 (2014).

    Article  Google Scholar 

  14. 14.

    Baroncelli, L. et al. A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging. Hum. Mol. Genet. 25, 4186–4200 (2017).

    Article  Google Scholar 

  15. 15.

    McKeon, A., Vaughan, C. & Delanty, N. Seizure versus syncope. Lancet Neurol. 5, 171–180 (2006).

    Article  Google Scholar 

  16. 16.

    Medford, B. A., Bos, J. M. & Ackerman, M. J. Epilepsy misdiagnosed as long QT syndrome: it can go both ways. Congenit. Heart Dis. 9, E135–E139 (2014).

    Article  Google Scholar 

  17. 17.

    Taggart, N. W., Haglund, M. C., Tester, D. J. & Ackerman, M. J. Diagnostic miscues in congenital long-QT syndrome. Circulation. 115, 2613–2620 (2007).

    Article  Google Scholar 

  18. 18.

    Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiog. 28, 1–39.e14 (2015).

    Article  Google Scholar 

  19. 19.

    Levin, M. D. et al. Melanocyte-like cells in the heart and pulmonary veins contribute to atrial arrhythmia triggers. J. Clin. Invest. 119, 3420–3436 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Yang, Z. H. et al. Dietary palmitoleic acid attenuates atherosclerosis progression and hyperlipidemia in low‐density lipoprotein receptor‐deficient mice. Mol. Nutr. Food Res. 63, 1900120 (2019).

    Article  Google Scholar 

  21. 21.

    Kleiber, M. The Fire of Life: An Introduction to Animal Energetics. (Wiley, New York, 1961).

  22. 22.

    Meister, J. et al. Metabolic effects of skeletal muscle-specific deletion of beta-arrestin-1 and -2 in mice. PLoS Genet. 15, 1–17 (2019).

    Article  Google Scholar 

  23. 23.

    Team RCR: A language and environment for statistical computing. (2018). https://cran.microsoft.com/snapshot/2014-09-08/web/packages/dplR/vignettes/xdate-dplR.pdf.

  24. 24.

    Wickham H. Ggplot2, elegant graphics for data analysis. (2009). https://link.springer.com/book/10.1007%2F978-3-319-24277-4#about.

  25. 25.

    Crilley, J. G. et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol. 41, 1776 (2003).

    CAS  Article  Google Scholar 

  26. 26.

    Ormerod, J. O. M., Frenneaux, M. P. & Sherrid, M. V. Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat. Rev. Cardiol. 13, 677–687 (2016).

    CAS  Article  Google Scholar 

  27. 27.

    Maron, B. J., Gottdiener, J. S., Bonow, R. O. & Epstein, S. E. Hypertrophic cardiomyopathy with unusual locations of left ventricular hypertrophy undetectable by m-mode echocardiography. Identification by wide-angle two-dimensional echocardiography. Circulation. 63, 409–418 (1981).

    CAS  Article  Google Scholar 

  28. 28.

    Cutler, M. J., Jeyaraj, D. & Rosenbaum, D. S. Cardiac electrical remodeling in health and disease. Trends Pharmacol. Sci. 32, 174–180 (2011).

    CAS  Article  Google Scholar 

  29. 29.

    Hill, J. A. Electrical remodeling in cardiac hypertrophy. Trends Cardiovas. Med. 13, 316–322 (2003).

    CAS  Article  Google Scholar 

  30. 30.

    Hill, J. A. Hypertrophic reprogramming of the left ventricle: translation to the ECG. J. Electrocardiol. 45, 624–629 (2012).

    Article  Google Scholar 

  31. 31.

    Wang, Y. & Hill, J. A. Electrophysiological remodeling in heart failure. J. Mol. Cell. Cardiol. 48, 619–632 (2010).

    CAS  Article  Google Scholar 

  32. 32.

    Heinrich, T. & Ingwall, J. S. Creatine—a dispensable metabolite? Circ. Res. 112, 878–880 (2013).

    Article  Google Scholar 

  33. 33.

    Schneider, J. E. et al. Cardiac structure and function during ageing in energetically compromised guanidinoacetate n-methyltransferase (GAMT)-knockout mice—a one year longitudinal mri study. J. Cardiovasc. Magn. Reson. 10, 9 (2008).

    Article  Google Scholar 

  34. 34.

    Schneider, J. E. et al. In vivo cardiac 1h-mrs in the mouse. Magn. Reson. Med. 52, 1029–1035 (2004).

    CAS  Article  Google Scholar 

  35. 35.

    Hove, M. T. et al. Creatine uptake in mouse hearts with genetically altered creatine levels. J. Mol. Cell. Cardiol. 45, 453–459 (2008).

    Article  Google Scholar 

  36. 36.

    Dzeja, P. P. et al. Rearrangement of energetic and substrate utilization networks compensate for chronic myocardial creatine kinase deficiency. J. Physiol. 589, 5193–5211 (2011).

    CAS  Article  Google Scholar 

  37. 37.

    Craig, L. et al. Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ. Res. 112, 945–955 (2013).

    Article  Google Scholar 

  38. 38.

    Hove, M. T. et al. Reduced inotropic reserve and increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-n-methyltransferase–knockout mice. Circulation. 111, 2477–2485 (2005).

    Article  Google Scholar 

  39. 39.

    Faller, K. M. E. et al. Impaired cardiac contractile function in arginine: glycine amidinotransferase knockout mice devoid of creatine is rescued by homoarginine but not creatine. Cardiovasc. Res. 114, 417–430 (2018).

    CAS  Article  Google Scholar 

  40. 40.

    Tian, R. & Ingwall, J. S. Energetic basis for reduced contractile reserve in isolated rat hearts. Am. J. Physiol. 270, H1207–H1216 (1996).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The National Center for Advancing Translational Sciences (NCATS), NICHD, National Institute of Mental Health (NIMH), and National Heart, Lung, and Blood Institute (NHLBI) intramural programs funded this work. We express our sincere gratitude to the subjects and their families for supporting this work. We also thank the Association for Creatine Deficiencies. The Slc6a8−/y mice were provided by Laura Baroncelli (Italian National Research Council). We acknowledge support by Lumos Pharmaceuticals and Ultragenyx. We also acknowledge the NHLBI pathology and mouse phenotyping cores for their assistance in data collection and data analysis. Each author has reviewed the manuscript and has agreed to its submission.

Author information

Affiliations

Authors

Contributions

Conceptualization: M.D.L., S.B., F.D.P. Data curation: M.D.L., S.B., A.S.M., N.X.C., A.D.D., D.H., J.F.G., A.T., J.M., J.P., N.G., D.S., C.F.S., C.A.W., Z.X.Y., A.S.C., F.D.P., F.H.S. Formal analysis: M.D.L., S.B., A.S.M. N.X.C., A.D.D., J.F.G., A.T., J.M., N.G., D.S., B.K., C.F.S., C.A.W., Z.X.Y., A.S.C., F.D.P., F.H.S. Funding acquisition: F.D.P. Investigation: M.D.L., S.B., A.S.M. N.X.C., A.D.D., J.F.G., N.G., D.S., Z.X.Y., C.A.W., F.D.P., F.H.S. Methodology: M.D.L., S.B., A.D.D., FDP, Z.X.Y., F.H.S. Supervision: M.D.L., S.B., F.D.P., F.H.S. Visualization: M.D.L., Z.X.Y., A.S.M., F.H.S. Writing & editing: M.D.L., S.B., A.S.M., N.X.C., A.D.D., D.H., J.F.G., A.T., J.M., J.P., N.G., D.S., C.F.S., C.A.W., Z.X.Y., B.K., A.S.C., F.D.P., F.H.S.

Corresponding author

Correspondence to Mark D. Levin.

Ethics declarations

Ethics declaration

Study approval was obtained from the IRB at the National Institute of Child Health and Human Development (NICHD), NIH. All guidelines for good clinical practice were followed. Guardians provided written consent. Assent was obtained when possible. Animal studies: All studied experiments performed had prior approval from NICHD animal studies committee and were carried out in strict compliance with all NIH guidelines and ethical regulations.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Levin, M.D., Bianconi, S., Smith, A. et al. X-linked creatine transporter deficiency results in prolonged QTc and increased sudden death risk in humans and disease model. Genet Med (2021). https://doi.org/10.1038/s41436-021-01224-8

Download citation

Search

Quick links